Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Lipitor Settlement With Pfizer Could Double Indian Firm Sales

This article was originally published in PharmAsia News

Executive Summary

The patent suit settlement Pfizer against Ranbaxy Laboratories could mean sales by India's largest drug maker will double within the next three years. The settlement ended Pfizer's suit against Ranbaxy and its generic of the U.S. company's Lipitor (atorvastatin). Last year, Lipitor brought $12.7 billion in sales to Pfizer, so the settlement allowing Ranbaxy to market a generic ahead of the expiration date for the drug patent could earn the Indian drug maker $2 billion, more than the firm's $1.78 billion in sales last year. Ranbaxy is allowed to begin marketing its generic in Canada after Nov. 30, and in the U.S. after Nov. 30, 2011. (Click here for more

Related Content

Ranbaxy Forecasts Conservative Growth, Remains Silent On Atorvastatin Launch, U.S. FDA Action



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts